Active · per the CBE, 1 October 2026

Apotheek Devos

BE0888712416

Rechtspersoon Private limited company 1 establishment

Apotheek Devos is a pharmacy in Halle. Private Limited, started on 12 April 2007, 1 establishment.

Alsembergsesteenweg 91, 1501 Halle

Behind the company: Bart Vandekerckhove, Pharma Invest Devos BV, Liesbet Devos.

Active for

19 year, 5 months

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

  • Two loss years in a row NBB

    Negative result in 2024 and 2025.

  • Tight liquidity NBB

    Cash and receivables cover 35 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Apotheek Devos from Halle, company number BE0888712416, closed financial year 2025 with a result of € -24,132 after tax. For that financial year Apotheek Devos recorded a gross margin of € 166,448 and equity of € 13,338. Compared with financial year 2024, the result moved from € -36,501 to € -24,132. The company made a loss. The buffer shrank hard: equity is 64 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.

What it is worth Shrank hard

€ 13,338

▼ 64% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -24,132

▲ 34 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 87,374

▼ 7% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 938.

People and assets in 2025

Full-time equivalents

1.6

▲ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 85,582

▲ 4% vs 2024

€ 53,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 7,232

▲ € 5,693 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 8 years to go

€ 658,206

▼ 9% vs 2024

€ 70,183 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 72,074

▼ 16% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 11,061

▼ 30% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
2022202320242025Change 2024 → 2025
Gross margin € 199,681 € 143,313 € 154,658 € 166,448 ▲ 8%
Profit after taxes € 47,117 € -31,997 € -36,501 € -24,132 ▲ € 12,369
Equity € 105,968 € 73,971 € 37,470 € 13,338 ▼ 64%
Total debts € 1,034,570 € 966,507 € 997,634 € 1,003,276 ▲ 1%
Cash € 119,393 € 64,245 € 93,899 € 87,374 ▼ 7%
Land & buildings € 749,966 € 695,757 € 645,509 € 600,241 ▼ 7%
Retained profit € 93,568 € 61,571 € 25,070 € 938 ▼ 96%
Bank debt € 830,637 € 793,783 € 726,780 € 658,206 ▼ 9%
Balance sheet total € 1,140,537 € 1,040,477 € 1,035,104 € 1,016,614 ▼ 2%
Employees (FTE) 1.3 1.3 1.3 1.6 ▲ 0.3

Key figures of Apotheek Devos, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Apotheek Devos?

What happened at Apotheek Devos in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: loss of € 24,132. Source: NBB ↗
  • New establishment in Halle. KBO
  • Start of the company according to the CBE. KBO

In short

From € 47,117 profit in 2022 to € 24,132 loss in 2025.

Best year ever: 2022, with € 47,117 profit.

On average € 104,000 of value added per employee in 2025.

Management

The stake of Pharma Invest Devos comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Apotheek Devos

Behind Apotheek Devos are Bart Vandekerckhove, Pharma Invest Devos BV and Liesbet Devos. The shares are held by Pharma Invest Devos (99%).

See the full network in the app

Directors

According to the 2025 annual accounts

Bart Vandekerckhove

Director

Pharma Invest Devos BV

Director · represented by Liesbet Devos

Liesbet Devos

Director

Also active at: Pharma Invest Devos

Shareholders

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Alsembergsesteenweg 91

1501 Halle

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0888.712.416
VAT number
BE 0888.712.416
Registered office
Alsembergsesteenweg 91, 1501 Halle
Names & denominations
Apotheek Devos
Enterprise type
Rechtspersoon
Legal form
Private limited company
Legal situation
Normale toestand
Start date
12 April 2007
Peppol
Active · Active since 7 Dec 2025
Activities · NACE

Apotheken

Apothekers

Frequently asked questions

What does Apotheek Devos do?
Apotheek Devos is a pharmacy in Halle. Private Limited, started on 12 April 2007, 1 establishment.
What is the address of Apotheek Devos?
The registered office of Apotheek Devos is located at Alsembergsesteenweg 91, 1501 Halle.
Is Apotheek Devos still active?
Yes. According to the CBE (1 October 2026) Apotheek Devos is active, legal situation “Normale toestand”, started on 12 April 2007.
Is Apotheek Devos registered on Peppol?
Yes, Apotheek Devos is registered on the Peppol network with ID 0208:0888712416.
What is the enterprise number of Apotheek Devos?
The enterprise number of Apotheek Devos is BE0888712416.
When was Apotheek Devos founded?
Apotheek Devos was founded on 12 April 2007.